Obesity Connect
  • Saved

2w
Background Image DesktopBackground Image Mobile

Obesity is increasingly recognized as a chronic inflammatory condition associated with altered metabolic signaling, insulin resistance, and systemic health complications. Growing evidence supports the importance of early, sustained approaches to long-term weight management.

See how obesity affects whole-body health

  • 2w
    obesity is a large issue because we know that it affects so many system functions and has an overall poor contribution to major disorders i.e. diabetes, htn, arthritis, dementia, cva Show More
  • 1mo
    A very complicated disease with protean manifestations. The #1 killer in the US.

Show More Comments

  • Saved

2w
The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review. - PubMed

The landscape of adult obesity in Malaysia: a mapping of evidence and contemporary narrative review. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42699752

Explore the metabolic risks of obesity in Malaysia and the need for coordinated policy efforts. Examine key obesity management strategies despite existing frameworks.


Metabolic risk starts below BMI 23 kg/m, with waist-to-height ratio >0.5 as an unhealthy threshold. Descriptive epidemiology dominates, with scarce longitudinal and experimental studies.

  • Saved

3w
How do safety and tolerability influence obesity treatment decisions?

Obesity management has evolved with newer pharmacologic therapies demonstrating meaningful efficacy, yet safety and tolerability remain central to treatment selection. Adverse effects, patient preferences, and long-term adherence all influence whether a treatment is started, continued, or switched in routine practice.

Gastrointestinal adverse events are among the most commonly reported considerations with current pharmacologic therapies for obesity, including nausea, vomiting, and diarrhea. These effects are often mild to moderate and more frequent during dose escalation, but they can still affect treatment persistence. Safety profiles vary across therapeutic classes, and clinicians must also consider less common adverse events, such as gastrointestinal complications or gallbladder-related events, as well as class-specific considerations that may require monitoring.

Patient factors should guide therapy choice, including comorbidities, prior treatment experience, weight-loss goals, and the likelihood of sustained adherence. In practice, the most appropriate option is often the one that best balances efficacy with an acceptable safety profile for the individual patient.

How do you weigh efficacy versus tolerability when selecting pharmacologic therapies for obesity? What patient factors most influence your decision to initiate or switch treatment in obesity management?

  • 3w
    In general, i go with the most efficacious medicine.
  • 1mo
    Patient factors that influence my decision are affordability, comorbidities, and contraindications. I discuss possible side effects, especially with GLP-1s and ways for the patient to help prevent side effects. If Show More

Show More Comments

  • Saved

3w
case study

Patient Background:

Mr. C is a 52-year-old male with a BMI of 37 kg/m² and a 10-year history of obesity with multiple prior attempts at sustained weight loss through calorie restriction and exercise.

Comorbidities include hypertension (amlodipine 10 mg), dyslipidemia (atorvastatin 40 mg), prediabetes (HbA1c 6.2%), and obstructive sleep apnea managed with CPAP. He is a non-smoker. Family history includes paternal myocardial infarction at age 58. He is motivated for pharmacologic intervention and has enrolled in a structured lifestyle program.

Assessment & Diagnosis:

Waist circumference: 116 cm. BP: 138/86 mmHg. Fasting glucose: 108 mg/dL. LDL-C: 118 mg/dL.…read more

He is an appropriate candidate for chronic weight management therapy. Treatment selection was guided by shared decision-making, cardiometabolic risk profile, prior weight-management history, and patient preference.

The care team initiates a once-weekly subcutaneous GLP-1 receptor agonist with gradual dose escalation over 16–20 weeks to improve tolerability.

In the STEP 1 trial (n=1,961), participants treated with semaglutide achieved a mean weight loss of 14.9% vs 2.4% with placebo at 68 weeks (p<0.001).

Common adverse effects discussed with the patient include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation.

  1. Please provide a minimum of a 3 sentence response.
  2. 1.Which comorbidities support GLP-1 RA therapy in this patient?
  3. 2.What counseling strategies help minimize GI adverse effects during GLP-1 RA dose escalation?

Show Less

  • 3w
    Obesity, hyperlipidemia, prediabetes and hypertension. I give the patients a script for Zofran prophylactically. Advise very small portions.
  • 3mo
    Patient's bmi over 27 support us of GLP-1. Also pt is prediabetic and GLP-1 should have a great impact on sugars. Furthermore, his Obstructive Show More

Show More Comments

  • Saved

3w
School-based diet and physical activity interventions and weight-related outcomes among children and adolescents in Africa: a systematic review and meta-analysis. - PubMed

School-based diet and physical activity interventions and weight-related outcomes among children and adolescents in Africa: a systematic review and meta-analysis. - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/42668382

Investigate the effects of school-based diet and physical activity programs on obesity among African youth. The study highlights modest improvements in adiposity.


School-based interventions in Africa showed modest improvements in adiposity among children, but the overall effect on BMI-for-age was not significant.